VIII

Sovos Brands Completes the Sale of Birch Benders

Retrieved on: 
Monday, January 9, 2023
Sale, Brynwood Partners, Growth, EBITDA, VIII, Breakfast

LOUISVILLE, Colo., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Sovos Brands, Inc. (“Sovos Brands” or the “Company”) (Nasdaq: SOVO), one of the fastest-growing food companies of scale in the United States, today announced that it has completed the divestiture of the Birch Benders brand and related assets to Hometown Food Company, a portfolio company controlled by Brynwood Partners VIII L.P.

Key Points: 
  • LOUISVILLE, Colo., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Sovos Brands, Inc. (“Sovos Brands” or the “Company”) (Nasdaq: SOVO), one of the fastest-growing food companies of scale in the United States, today announced that it has completed the divestiture of the Birch Benders brand and related assets to Hometown Food Company, a portfolio company controlled by Brynwood Partners VIII L.P.
  • “We are pleased to complete the sale of Birch Benders to Hometown Food Company, a business already home to a number of popular breakfast and baking brands,” commented Todd Lachman, President and Chief Executive Officer.
  • “Today’s announcement reflects Sovos Brands’ continued commitment to growing our core Rao’s and Noosa brands and, in particular, accelerating Rao’s to $1 billion in net sales and beyond.
  • As we look ahead, Sovos Brands will be a more focused business that is better-positioned to drive sustainable sector leading growth for years to come.”
    Given the timing of the transaction, the divestiture of Birch Benders will have no impact on the Company’s fiscal 2022 net sales and adjusted EBITDA.

Bleeding Disorders Treatment Global Market Report 2022: Ukraine-Russia War Impact

Retrieved on: 
Tuesday, January 3, 2023
Organization, Liver disease, Takeda, Trauma, Octapharma, DDAVP, Patient, Von Willebrand disease, Pfizer, CSL Behring, University, World Federation of Hemophilia, Growth, Bleeding, Half-life, Shire (pharmaceutical company), COVID-19, Menstruation, Biomedical technology, Blood, AbbVie, Plasma, World government, DNA, Coagulopathy, Hormone replacement therapy, Biogen, Takeda Pharmaceutical Company, Ferring Pharmaceuticals, University of Oslo, Bayer, Geography, Novartis, VIII, Hospital, Novo Nordisk, Pharmaceutical industry, Birth control, Medical device, Haemophilia

The bleeding disorders treatment market is expected to grow to $18.50 billion in 2026 at a CAGR of 7.9%.

Key Points: 
  • The bleeding disorders treatment market is expected to grow to $18.50 billion in 2026 at a CAGR of 7.9%.
  • The regions covered in the bleeding disorders treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • The bleeding disorders treatment market research report is one of a series of new reports that provides Bleeding disorders treatment market statistics, including bleeding disorders treatment industry global market size, regional shares, competitors with bleeding disorders treatment market share, detailed Bleeding disorders treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the bleeding disorders treatment industry.
  • This bleeding disorders treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Spark Therapeutics Announces Updated Phase 1/2 Study Results Supporting the Durability of Investigational Gene Therapy SPK-8011 in Patients With Hemophilia A

Retrieved on: 
Monday, December 12, 2022
ROG, AIRS, Spark Therapeutics, Safety, ABR, Haemophilia, ASH, VIII, Hoffmann-La Roche, Society, Therapy, RO, Patient, Pharmaceutical industry

“The updated results of this Phase 1/2 study add to the growing body of preliminary evidence suggesting that investigational SPK-8011 provides durable FVIII expression for the treatment of hemophilia A,” said Gallia Levy, M.D., Ph.D., Chief Medical & Product Strategy Officer, Spark Therapeutics.

Key Points: 
  • “The updated results of this Phase 1/2 study add to the growing body of preliminary evidence suggesting that investigational SPK-8011 provides durable FVIII expression for the treatment of hemophilia A,” said Gallia Levy, M.D., Ph.D., Chief Medical & Product Strategy Officer, Spark Therapeutics.
  • “At Spark, we are focused on developing a gene therapy for people with hemophilia A that demonstrates safety, predictability, efficacy, and durability at the lowest effective dose with an optimal immunomodulatory regimen.
  • Interim results from the phase 1/2 study were published online in the New England Journal of Medicine (NEJM) in November 2021.
  • (Trial identifier NCT03003533)
    We believe gene therapy has the potential to revolutionize medicine and improve the lives of patients with genetic and other serious diseases.

Ascension Healthcare Announces Positive Data from Phase 2 Study of XLR8 in Severe Haemophilia A Patients

Retrieved on: 
Monday, December 12, 2022
Haemophilia, Bleeding, Use, Prevalence, FDA, Factor VIII, University College London, Gold, VIII, PEGylation, Osteoarthritis, Coronavirus Scientific Advisory Board (Turkey), Fibrinolysis, Potency, Haemophilia A, History, Standard of care, XLR8, Risk, Male, Ascension, Patient, Vaccine, Pharmaceutical industry, Birth control

Haemophilia A patients lack sufficient factor VIII clotting factors which leaves them at risk of uncontrolled bleeding.

Key Points: 
  • Haemophilia A patients lack sufficient factor VIII clotting factors which leaves them at risk of uncontrolled bleeding.
  • This trial was designed to demonstrate that administration of PEGLip, following a normal dose of prophylactic, standard half-life FVIII in severe, non-inhibitor Haemophilia A patients can both enhance clotting activity and extend the dosing interval beyond FVIII administered alone.
  • Results from the study demonstrated that clotting activity was significantly improved at certain time points over baseline and over injection of FVIII alone.
  • The therapy is primarily aimed at f severe patients who are receiving standard of care prophylaxis with intravenous FVIII, where the adjuvant will extend their FVIII dosing interval, thereby improving compliance.

Ascension Healthcare Announces Positive Data from Phase 2 Study of SelectAte in Severe Haemophilia A Patients with inhibitors

Retrieved on: 
Monday, December 12, 2022
Haemophilia, Bleeding, Prevalence, Antibody, FDA, Factor VIII, University College London, VIII, Osteoarthritis, Coronavirus Scientific Advisory Board (Turkey), Fibrinolysis, Haemophilia A, History, Risk, Male, Selective serotonin reuptake inhibitor, Ascension, Patient, Pharmaceutical industry

SelectAte is a proprietary pre-mixed combination of a recombinant factor VIII clotting protein and PEGylated liposomes (PEGLip), co-injected intravenously.

Key Points: 
  • SelectAte is a proprietary pre-mixed combination of a recombinant factor VIII clotting protein and PEGylated liposomes (PEGLip), co-injected intravenously.
  • These results were achieved in both non-inhibitor patients and also those that were both inhibitor prone and presenting with low levels of inhibitors.
  • SelectAte is being developed to treat severe HA patients who have developed inhibitors (neutralising antibodies) to FVIII.
  • Approximately 30% of severe HA patients develop inhibitors to prophylactic FVIII replacement therapy, rendering such therapy ineffective.

Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia

Retrieved on: 
Saturday, December 10, 2022
Haemophilia A, Hemostasis, Bleeding, Protein, Disorder, Annual report, Person, FDA, DRS, Omicron, Safety, Arthropathy, Maintenance, Coagulation, Pharmacokinetics, Factor VIII, Haemophilia, ASH, Hemarthrosis, Thrombin, Doctor of Philosophy, APC, VIII, Joint, Factor IX, PWH, Research, OLE, Risk, Male, COVID-19, Volunteering, Patient, Coagulopathy, Pharmaceutical industry, Delta

The interventional studies include PRESent-2 (moderately severe to severe hemophilia B without inhibitors, and severe hemophilia A with and without inhibitors) and PRESent-3 (hemophilia B with inhibitors).

Key Points: 
  • The interventional studies include PRESent-2 (moderately severe to severe hemophilia B without inhibitors, and severe hemophilia A with and without inhibitors) and PRESent-3 (hemophilia B with inhibitors).
  • Yver and Baglin share the OLE data slides presented at ASH and discuss the SerpinPC registrational program within a recorded webcast now available on the Company’s website at https://investors.centessa.com/events-presentations .
  • SerpinPC is an investigational agent that has not been approved by the FDA or any other regulatory authority.
  • Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients.

Gores Holdings VIII, Inc. Announces Special Meeting of Stockholders to Obtain Stockholder Approval to Liquidate in 2022

Retrieved on: 
Thursday, December 15, 2022
Professional Services, Finance, Acquisition, Eastern, Nashville Charter Amendment 1, Person, Finance Secretary (India), Computershare, United Wholesale Mortgage, Proposal, VIII, Hostess, Eastern Time Zone, The Gores Group, Common, Common stock, Commission, Proxy, PAE, Holding, Attention, Security (finance), Polestar

The Company expects to complete the Mandatory Redemption on or around December 30, 2022 if stockholders approve the Proposals.

Key Points: 
  • The Company expects to complete the Mandatory Redemption on or around December 30, 2022 if stockholders approve the Proposals.
  • Additionally, the last day of trading of the Public Shares will be December 29, 2022 if stockholders approve the Proposals.
  • Gores Holdings VIII, Inc. is a special purpose acquisition company sponsored by an affiliate of The Gores Group, LLC, founded by Alec Gores.
  • To date, affiliates of The Gores Group have closed nine business combinations representing approximately $58 billion in transaction value, which include: Hostess (Gores Holdings, Inc.); Verra Mobility (Gores Holdings II, Inc.); PAE (Gores Holdings III, Inc.); Luminar (Gores Metropoulos, Inc.); United Wholesale Mortgage (Gores Holdings IV, Inc.); Ardagh Metal Packaging (Gores Holdings V, Inc.); Matterport (Gores Holdings VI, Inc.); Sonder (Gores Metropoulos II, Inc.); and Polestar (Gores Guggenheim).

Immune Checkpoint Inhibitors Clinical Trial Analysis 2022: PD-1/ PD-L1 Blockades Show Promise as New Form of Targeted Cancer Therapy - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 15, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Geography, VII, Melanoma, Microsoft PowerPoint, Quality of life, Neoplasm, Clinical trial, MS, FDA, Hospital, Table, Cancer, Microsoft Excel, Death, PD-1, Fatality, Pembrolizumab, VIII, Appendix, Clinical, III, Organization, Immune system, Research, Nivolumab, Disease, Publication, Patient, PD-L1, Pharmaceutical industry, Vaccine, Palladium, Bookkeeping, Medical imaging, PubMed

The "Immune Checkpoint Inhibitors: Analysis of Clinical Trial Results (Featuring Recently Published Trial Results, Contemporary Pipeline Review, Clinical Trial Analysis, Clinical Publications Analysis, and Estimated Time to Market Analysis for Novel Drug Candidates)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Immune Checkpoint Inhibitors: Analysis of Clinical Trial Results (Featuring Recently Published Trial Results, Contemporary Pipeline Review, Clinical Trial Analysis, Clinical Publications Analysis, and Estimated Time to Market Analysis for Novel Drug Candidates)" report has been added to ResearchAndMarkets.com's offering.
  • Additionally, the non-specific and highly toxic nature of both chemotherapy and radiation therapy is known to significantly deteriorate quality of life.
  • Over the last couple of decades, several targeted, anti-cancer therapies have been developed, and many are already available in the market.
  • Section III features data from clinicaltrials.gov which was used for a historical clinical trial analysis of studies featuring PD-1 and PD-L1 inhibitors.

Asante Capital Group Strengthens Team, Expands Global Footprint and Extends Record of Successful Fund Closes in 2022

Retrieved on: 
Thursday, December 15, 2022
Banking, Professional Services, Finance, Vista Equity Partners, Asante Africa Foundation, AnaCap Financial Partners, Partnership, CO2, Asante, Partner (business rank), Growth, Capital Group Companies, VIII, Education, Partner, EUR, Video game, Renewable energy, Financial services, GP

In 2022, Asante saw an almost 20% increase in employee headcount, showcasing the firms commitment to bolstering its team with highly driven and talented individuals.

Key Points: 
  • In 2022, Asante saw an almost 20% increase in employee headcount, showcasing the firms commitment to bolstering its team with highly driven and talented individuals.
  • In addition, as a leading global fundraising advisor, Asante supported numerous successful fund closes across the globe in various sectors, including technology and impact.
  • Asante also continued to grow its partnership with Asante Africa Foundation, which is committed to providing educational opportunities to children in East Africa.
  • Asante Capital Group is a leading independent private equity placement and advisory group.

Hemophilia Treatment Market Report 2022-2030: Growth Influencers Include Preference for Prophylactic Treatment, Rise in Diagnosis Rate, Significant Rise in Usage of Recombinant Coagulation Factor - ResearchAndMarkets.com

Retrieved on: 
Monday, December 12, 2022
Health, Biotechnology, Degenerative disease, World Blood Donor Day, Haemophilia, Pregnancy, Diagnosis, Plasma, Prevalence, Haemophilia A, Research, XI, Disease, Coagulopathy, Incidence, Haemophilia B, Government, Growth, VIII, Factor XI, Infection, Blood, Risk, Renewable energy, Vaccine, Agriculture, Marketing

The product types studied for analyzing the overall global hemophilia treatment market are majorly segmented into plasma derived coagulation factor concentrates, recombinant coagulation factor concentrates, antifibrinolytic agents and desmopressin.

Key Points: 
  • The product types studied for analyzing the overall global hemophilia treatment market are majorly segmented into plasma derived coagulation factor concentrates, recombinant coagulation factor concentrates, antifibrinolytic agents and desmopressin.
  • The global hemophilia treatment market is segmented by hemophilia type into Hemophilia A, Hemophilia B and others.
  • With increase in healthcare expenditure, preference for prophylactic treatment, rise in diagnosis rate, significant rise in usage of recombinant coagulation factor are major contributors in growth of haemophilia market.
  • Hemophilia A is four times more prevalent than hemophilia B and thus dominates the global hemophilia treatment market.